Oxford Nanopore to develop test in deal with PathoQuest

Nanopore sequencing product developer Oxford Nanopore Technologies PLC has signed a deal with genomics experts PathoQuest SAS to develop an integration site analysis test.

According to the companies the test will provide 'a good manufacturing practice validated nanopore sequencing-based commercial testing service to the biopharma industry'. A service designed to address the needs of industrial developers and biological product manufacturers.

Oxford Nanopore’s technology can accurately read any length of native DNA, enabling the identification and comprehensive sequence assessment of genomic insertion sites. Additionally, PathoQuest’s ISA test provides benefits that other traditional sequencing methods cannot.

Chief executive at Oxford Nanopore Gordon Sanghera said: “We are excited to be working with PathoQuest to develop and offer the first Good Manufacturing Practice (GMP) accredited Integration Site Analysis test with nanopore sequencing. We believe this will have a significant future impact by improving test accuracy and turnaround times for genetic characterisation for multiple applications in biopharma.

''Nanopore sequencing offers a transformational new approach for robust and accurate genetic characterisation of biological materials, which we believe will enable the release of novel therapeutics with more certainty and safety assurance than ever before."

Read more - UKAEA’s CEO celebrates double recognition